Ann M. Bode

27.6k total citations · 4 hit papers
422 papers, 21.1k citations indexed

About

Ann M. Bode is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Ann M. Bode has authored 422 papers receiving a total of 21.1k indexed citations (citations by other indexed papers that have themselves been cited), including 282 papers in Molecular Biology, 131 papers in Oncology and 69 papers in Cancer Research. Recurrent topics in Ann M. Bode's work include Cancer-related Molecular Pathways (59 papers), Melanoma and MAPK Pathways (43 papers) and PI3K/AKT/mTOR signaling in cancer (29 papers). Ann M. Bode is often cited by papers focused on Cancer-related Molecular Pathways (59 papers), Melanoma and MAPK Pathways (43 papers) and PI3K/AKT/mTOR signaling in cancer (29 papers). Ann M. Bode collaborates with scholars based in United States, China and South Korea. Ann M. Bode's co-authors include Zigang Dong, Richard C. Rose, Weiya Ma, Ki Won Lee, Yong‐Yeon Cho, Feng Zhu, Mee‐Hyun Lee, Ya Cao, Xiangjian Luo and Mengqiu Song and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Ann M. Bode

417 papers receiving 20.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Post-translational modification of p53 in tumorigenesis

2004 990 citations Ann M. Bode, Zigang Dong profile →
AKT as a Therapeutic Target for Cancer

2019 617 citations Ann M. Bode, Zigang Dong et al. Cancer Research profile →
ACSL family: The regulatory mechanisms and therapeutic implications in cancer

2021 201 citations Ann M. Bode, Xiangjian Luo et al. European Journal of Pharmacology profile →
Targeting CDK1 in cancer: mechanisms and implications

2023 92 citations Ann M. Bode et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ann M. Bode United States	77	12.4k	4.1k	3.3k	2.4k	1.7k	422	21.1k
Zigang Dong United States	88	17.1k 1.4×	5.7k 1.4×	4.4k 1.3×	3.1k 1.3×	2.2k 1.3×	578	28.0k
Kwang Seok Ahn South Korea	77	10.5k 0.8×	3.7k 0.9×	3.1k 1.0×	1.9k 0.8×	1.1k 0.6×	361	19.0k
Nihal Ahmad United States	71	8.5k 0.7×	3.1k 0.7×	2.2k 0.7×	4.9k 2.1×	3.4k 2.0×	240	22.9k
Q. Ping Dou United States	74	9.3k 0.7×	6.2k 1.5×	1.6k 0.5×	2.4k 1.0×	1.0k 0.6×	280	17.8k
Alan Prem Kumar Singapore	84	11.2k 0.9×	3.7k 0.9×	4.2k 1.3×	1.8k 0.8×	604 0.3×	251	19.3k
William P. Steward United Kingdom	67	7.4k 0.6×	4.3k 1.0×	2.0k 0.6×	1.7k 0.7×	1.7k 1.0×	221	18.3k
Peter J. Houghton United States	86	15.6k 1.3×	7.5k 1.8×	3.2k 1.0×	2.0k 0.8×	1.0k 0.6×	571	28.8k
Anupam Bishayee United States	79	9.5k 0.8×	2.3k 0.6×	2.3k 0.7×	1.6k 0.7×	2.1k 1.2×	312	20.2k
Ian A. Blair United States	69	10.0k 0.8×	2.9k 0.7×	2.9k 0.9×	706 0.3×	1.2k 0.7×	421	21.1k
Chuanshu Huang United States	61	7.9k 0.6×	2.5k 0.6×	2.8k 0.8×	1.2k 0.5×	911 0.5×	301	13.0k

Countries citing papers authored by Ann M. Bode

Since Specialization

Citations

This map shows the geographic impact of Ann M. Bode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann M. Bode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann M. Bode more than expected).

Fields of papers citing papers by Ann M. Bode

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann M. Bode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann M. Bode. The network helps show where Ann M. Bode may publish in the future.

Co-authorship network of co-authors of Ann M. Bode

This figure shows the co-authorship network connecting the top 25 collaborators of Ann M. Bode. A scholar is included among the top collaborators of Ann M. Bode based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann M. Bode. Ann M. Bode is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bode, Ann M., et al.. (2024). Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(5). 189166–189166. 10 indexed citations

Bode, Ann M., et al.. (2024). The role of novel protein acylations in cancer. European Journal of Pharmacology. 979. 176841–176841. 6 indexed citations

Lee, Kun Y., Ke Yao, Seung Ho Shin, et al.. (2020). GSK3β-Mediated Expression of CUG-Translated WT1 Is Critical for Tumor Progression. Cancer Research. 81(4). 945–955. 7 indexed citations

Bai, Fang, Kangdong Liu, Hui‐Liang Li, et al.. (2017). Veratramine modulates AP-1-dependent gene transcription by directly binding to programmable DNA. Nucleic Acids Research. 46(2). 546–557. 23 indexed citations

Shen, Na, Fei Yan, Jiuxia Pang, et al.. (2017). Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia. Clinical Cancer Research. 23(20). 6254–6266. 31 indexed citations

Dickinson, Sally E., Karen Blohm‐Mangone, Erik R. Olson, et al.. (2016). Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. Cancer Prevention Research. 9(3). 215–224. 16 indexed citations

Lubet, Ronald A., James M. Scheiman, Ann M. Bode, et al.. (2015). Prevention of Chemically Induced Urinary Bladder Cancers by Naproxen: Protocols to Reduce Gastric Toxicity in Humans Do Not Alter Preventive Efficacy. Cancer Prevention Research. 8(4). 296–302. 13 indexed citations

Lim, Do Young, Mee‐Hyun Lee, Seung Ho Shin, et al.. (2014). (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Suppresses Solar UV-Induced Skin Carcinogenesis by Targeting PI3K, ERK1/2, and p38. Cancer Prevention Research. 7(8). 856–865. 7 indexed citations

Yao, Ke, Hanyong Chen, Kangdong Liu, et al.. (2014). Kaempferol Targets RSK2 and MSK1 to Suppress UV Radiation-Induced Skin Cancer. Cancer Prevention Research. 7(9). 958–967. 58 indexed citations

10.

Nicastro, Holly L., Clinton J. Grubbs, M. Margaret Juliana, et al.. (2013). Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model. Cancer Prevention Research. 7(2). 246–254. 20 indexed citations

11.

Song, Nu Ry, Eun-Jung Lee, Sanguine Byun, et al.. (2013). Isoangustone A, A Novel Licorice Compound, Inhibits Cell Proliferation by Targeting PI3K, MKK4, and MKK7 in Human Melanoma. Cancer Prevention Research. 6(12). 1293–1303. 24 indexed citations

12.

Byun, Sanguine, Sungyoung Lee, Ji‐Hoon Lee, et al.. (2013). USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. Clinical Cancer Research. 19(14). 3894–3904. 110 indexed citations

13.

Kim, Mi-Sung, Jong‐Eun Kim, Do Young Lim, et al.. (2013). Naproxen Induces Cell-Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting PI3K. Cancer Prevention Research. 7(2). 236–245. 69 indexed citations

14.

Li, Wei, Cong Peng, Mee‐Hyun Lee, et al.. (2013). TRAF4 Is a Critical Molecule for Akt Activation in Lung Cancer. Cancer Research. 73(23). 6938–6950. 91 indexed citations

15.

Lee, Sungyoung, Tae‐Gyu Lim, Hanyong Chen, et al.. (2013). Esculetin Suppresses Proliferation of Human Colon Cancer Cells by Directly Targeting β-Catenin. Cancer Prevention Research. 6(12). 1356–1364. 62 indexed citations

16.

Lü, Yan, Ming You, Zara Ghazoui, et al.. (2013). Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes. Cancer Prevention Research. 6(11). 1151–1161. 10 indexed citations

17.

Kim, Dong Joon, Yan Li, Kanamata Reddy, et al.. (2012). Novel TOPK Inhibitor HI-TOPK-032 Effectively Suppresses Colon Cancer Growth. Cancer Research. 72(12). 3060–3068. 88 indexed citations

18.

Urusova, Darya V., Jung‐Hyun Shim, Dong Joon Kim, et al.. (2011). Epigallocatechin-gallate Suppresses Tumorigenesis by Directly Targeting Pin1. Cancer Prevention Research. 4(9). 1366–1377. 96 indexed citations

19.

Kim, Dong Joon, Kanamata Reddy, Myoung Ok Kim, et al.. (2011). (3-Chloroacetyl)-indole, a Novel Allosteric AKT Inhibitor, Suppresses Colon Cancer Growth In Vitro and In Vivo. Cancer Prevention Research. 4(11). 1842–1851. 27 indexed citations

20.

Lee, Kyung‐Mi, Ki Won Lee, Ann M. Bode, Hyong Joo Lee, & Zigang Dong. (2009). Tpl2 Is a Key Mediator of Arsenite-Induced Signal Transduction. Cancer Research. 69(20). 8043–8049. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact